Scancell to merge with Neuphoria and list on Nasdaq, plans up to $89 million financing
The all-share merger would move Scancell's melanoma immunotherapy program to Nasdaq while Neuphoria stockholders receive contingent value rights tied to partnered assets.
SEC filing